Aberrant TRPM7 expression in human breast and pancreatic cancers is closely correlated with clinicopathological parameters, such as tumour grade, Ki‐67 proliferation index and patient survival time.22 This evidence concerns the gene TRPM7 and familial pancreatic carcinoma.